<DOC>
	<DOCNO>NCT00198237</DOCNO>
	<brief_summary>The primary objective study determine efficacy &amp; toxicity combine docetaxel &amp; capecitabine primary chemo subject w/ stage II-III breast cancer .</brief_summary>
	<brief_title>Genomic &amp; Proteomic Analysis Docetaxel &amp; Capecitabine Primary Chemo Stage II-III Breast Cancer</brief_title>
	<detailed_description>The primary objective study determine efficacy &amp; toxicity combine docetaxel &amp; capecitabine primary chemotherapy subject stage II-III breast cancer.Subjects randomize one two group : Docetaxel follow four cycle docetaxel &amp; capecitabine vs. capecitabine follow four cycle docetaxel capecitabine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm adenocarcinoma breast w/ Stage IIIII disease w/ primary tumor &gt; /=2cm clinically palpable axillary lymph node . Pretreatment core incisional bx w/ adequate tissue histology &amp; genomic/proteomic analysis . Primary tumor must bidimensionally measurable physical exam dx breast imaging . Measurements must obtain w/in 3 wks prior study entry . Adequate organ fxn : AGC &gt; 1500 ; Hb &gt; /=9.0 ; plts &gt; /=100K ; Crt &lt; /=2.0 ; Cacl Crt Clr &gt; /=50 ; total bili &lt; /=ULN ; LFTs &lt; 2.0 ULN ECOG performance status 01 Neg . pregnancy test Pts may definitive primary surgery . Metastatic breast cancer Any prior chemo hormonal therapy breast cancer Prior history malignancy w/in previous 5 yr . No active unresolved infection No major surgery w/in 2wks start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Stage II Breast Cancer</keyword>
	<keyword>Stage III Breast Cancer</keyword>
</DOC>